NCT07359742 Assessing Signatures for Fibrosis Detection in Chronic Liver Disease: A Step Beyond Conventional Biomarkers
| NCT ID | NCT07359742 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitair Ziekenhuis Brussel |
| Condition | Chronic Liver Disease (CLD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 110 participants |
| Start Date | 2026-05 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 110 participants in total. It began in 2026-05 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Morbidity and mortality of CLD is driven by the extent of liver fibrosis, characterized by scar formation and disruption of the normal liver architecture. HSCs play a central role in liver fibrosis development. When hepatocytes are damaged, HSCs undergo myofibroblast differentiation, transitioning into an activated state. So far, no efficient biomarkers can estimate the degree of HSC activation or reversal across all aetiologies of CLD, although this could be a more sensitive marker than fibrosis measurement which is secondary to HSC activation. This study aims to correlate biomarkers to the fibrosis stage in a larger cohort of patients with CLD across all aetiologies.
Eligibility Criteria
Inclusion Criteria: * ≥18y * Chronic liver disease: alcohol, metabolic dysfunction associated steatotic liver disease, viral hepatitis, autoimmune hepatitis, cholestatic liver disease and hemochromatosis Exclusion Criteria: * \<18y * Acute hepatitis * Contra-indication for transient elastography (Fibroscan®) such as ascites or overt heart failure.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07359742 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Liver Disease (CLD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07359742 currently recruiting?
Yes, NCT07359742 is actively recruiting participants. Contact the research team at silke.francois@uzbrussel.be for enrollment information.
Where is the NCT07359742 trial being conducted?
This trial is being conducted at Brussels, Belgium.
Who is sponsoring the NCT07359742 clinical trial?
NCT07359742 is sponsored by Universitair Ziekenhuis Brussel. The trial plans to enroll 110 participants.